Novel therapies for myelodysplastic syndromes

Hematology/Oncology Clinics of North America

Volumn 24, Issue 2, 2010, Pages 423-441

  Steensma, David P ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Clofarabine; Ezatiostat; Farnesyltransferase inhibitors; Histone deacetylase inhibitors; Laromustine; Myelodysplastic syndromes

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; 4 PHENYLBUTYRIC ACID; 5 AZA 2' DEOXYCYTIDINE; ALEMTUZUMAB; AZACITIDINE; BELINOSTAT; CLADRIBINE; CLOFARABINE; CLORETAZINE; CYTARABINE; ENTINOSTAT; EZATIOSTAT; FLUDARABINE; FR 901229; GAMMA GLUTAMYL S BENZYLCYSTEINYLPHENYLGLYCINE DIETHYL ESTER; GLUTATHIONE DERIVATIVE; HISTONE DEACETYLASE INHIBITOR; LENALIDOMIDE; LONAFARNIB; MELPHALAN; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; PANOBINOSTAT; ROMIDEPSIN; SNDX 275; THYMOCYTE ANTIBODY; TIPIFARNIB; TLK 199; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ANEMIA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTINUOUS INFUSION; CUTANEOUS T CELL LYMPHOMA; CYTOPENIA; DIARRHEA; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HAIRY CELL LEUKEMIA; HUMAN; HYPOALBUMINEMIA; HYPOCALCEMIA; KIDNEY FAILURE; LIVER TOXICITY; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; PROTEIN MODIFICATION; QT INTERVAL; QT PROLONGATION; REMISSION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; SOMNOLENCE; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSTEADINESS; VOMITING;

ADENINE NUCLEOTIDES; AGED; ALKYLATING AGENTS; ANTIMETABOLITES; ARABINONUCLEOSIDES; CLINICAL TRIALS AS TOPIC; DNA REPAIR; DRUG THERAPY, COMBINATION; DRUGS, INVESTIGATIONAL; ENZYME ACTIVATION; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; GLUTATHIONE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDRAZINES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MYELODYSPLASTIC SYNDROMES; QUINOLONES; SULFONAMIDES; THERAPIES, INVESTIGATIONAL;

EID: 77950533453     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2010.02.010     Document Type: Review

References (64)

1. Steensma D.P., Bennett J.M. The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc 2006, 81:104.
2. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223.
3. Kantarjian H., Issa J.P., Rosenfeld C.S., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006, 106:1794.
4. List A., Dewald G., Bennett J., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006, 355:1456.
5. Silverman L.R., Demakos E.P., Peterson B.L., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002, 20:2429.
6. Gore S.D., Hermes-DeSantis E.R. Future directions in myelodysplastic syndrome: newer agents and the role of combination approaches. Cancer Control 2008, 15(Suppl):40.
7. Griffiths E.A., Gore S.D. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Semin Hematol 2008, 45:23.
8. Anonymous Life expectancy in the United States. Centers for Disease Control Available at:, Accessed August 30, 2009. http://www.cdc.gov/nchs/data/hus/hus08.pdf.
9. Godde J.S., Ura K. Cracking the enigmatic linker histone code. J Biochem 2008, 143:287.
10. Lawless M.W., Norris S., O'Byrne K.J., et al. Targeting histone deacetylases for the treatment of disease. J Cell Mol Med 2009, 13:826.
11. Santini V., Gozzini A., Ferrari G. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application. Curr Drug Metab 2007, 8:383.
12. Yang X.J., Seto E. Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol Cell 2008, 31:449.
13. Kortenhorst M.S., Carducci M.A., Shabbeer S. Acetylation and histone deacetylase inhibitors in cancer. Cell Oncol 2006, 28:191.
14. Moradei O., Vaisburg A., Martell R.E. Histone deacetylase inhibitors in cancer therapy: new compounds and clinical update of benzamide-type agents. Curr Top Med Chem 2008, 8:841.
15. Stimson L., Wood V., Khan O., et al. HDAC inhibitor-based therapies and haematological malignancy. Ann Oncol 2009, 20:1293.
16. Figueroa M.E., Skrabanek L., Li Y., et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 2009, 114(16):3448-3458.
17. Kuendgen A., Lubbert M. Current status of epigenetic treatment in myelodysplastic syndromes. Ann Hematol 2008, 87:601.
18. Cang S., Ma Y., Liu D. New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. J Hematol Oncol 2009, 2:22.
19. Gojo I., Jiemjit A., Trepel J.B., et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 2007, 109:2781.
20. Gore S.D., Jiemjit A., Silverman L.B., et al. Combined methyltransferase/histone deacetylase inhibition with 5-azacitidine and MS-275 in patients with MDS, CMMoL and AML: clinical response, histone acetylation and DNA damage. ASH Annual Meeting Abstracts 2006, 108:517.
21. Gimsing P., Hansen M., Knudsen L.M., et al. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur J Haematol 2008, 81:170.
22. Klimek V.M., Fircanis S., Maslak P., et al. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin Cancer Res 2008, 14:826.
23. Ottmann O.G., Spencer A., Prince H.M., et al. Phase IA/II study of oral panobinostat (lbh589), a novel pan- deacetylase inhibitor (DACi) demonstrating efficacy in patients with advanced hematologic malignancies. ASH Annual Meeting Abstracts 2008, 112:958.
24. Kalff A., Shortt J., Farr J., et al. Laboratory tumor lysis syndrome complicating LBH589 therapy in a patient with acute myeloid leukemia. ASH Annual Meeting Abstracts 2006, 108:4554.
25. Gottlicher M., Minucci S., Zhu P., et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001, 20:6969.
26. Issa J.P., Castoro R., Ravandi-Kashani F., et al. Randomized phase ii study of combined epigenetic therapy: decitabine vs. decitabine and valproic acid in MDS and AML. ASH Annual Meeting Abstracts 2008, 112:228.
27. Siitonen T., Timonen T., Juvonen E., et al. Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes. Haematologica 2007, 92:1119.
28. Kuendgen A., Knipp S., Fox F., et al. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. Ann Hematol 2005, 84(Suppl 13):61.
29. Bug G., Ritter M., Wassmann B., et al. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer 2005, 104:2717.
30. Garcia-Manero G., Kantarjian H.M., Sanchez-Gonzalez B., et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood 2006, 108:3271.
31. Voso M.T., Santini V., Finelli C., et al. Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer Res 2009, 15:5002.
32. Gore S.D., Weng L.J., Figg W.D., et al. Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res 2002, 8:963.
33. Maslak P., Chanel S., Camacho L.H., et al. Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. Leukemia 2006, 20:212.
34. Garcia-Manero G., Assouline S., Cortes J., et al. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 2008, 112:981.
35. Garcia-Manero G., Yang A.S., Klimek V., et al. Phase I/II study of MGCD0103, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in combination with 5-azacitidine in higher-risk myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). ASH Annual Meeting Abstracts 2007, 110:444.
36. Anonymous Methylgene press release October 27, 2008 Available at:, Accessed February 17, 2010. http://www.fiercebiotech.com/press-releases/methylgene-reacquires-rights-mgcd0103-celgene-implements-plan-focus-development-propr.
37. Garcia-Manero G., Yang H., Bueso-Ramos C., et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008, 111:1060.
38. Ravandi F., Faderl S., Thomas D., et al. Phase I study of suberoylanilide hydroxamic acid (SAHA) and decitabine in patients with relapsed, refractory or poor prognosis leukemia. ASH Annual Meeting Abstracts 2007, 110:897.
39. Faoro L.N., Tefferi A., Mesa R.A. Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia. Eur J Haematol 2005, 74:117.
40. Holowiecki J., Grosicki S., Kyrcz-Krzemien S., et al. Addition of cladribine to the standard daunorubicine - cytarabine (DA 3+7) remission induction protocol (DAC) contrary to adjunct of fludarabine (DAF) improves the overall survival in untreated adults with acute myeloid leukemia aged up to 60 Y: a multicenter, randomized, phase III PALG AML 1/2004 DAF/DAC/DA study in 673 patients. ASH Annual Meeting Abstracts 2008, 112:133.
41. Parker J.E., Pagliuca A., Mijovic A., et al. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 1997, 99:939.
42. Kantarjian H.M., Jeha S., Gandhi V., et al. Clofarabine: past, present, and future. Leuk Lymphoma 1922, 48:2007.
43. Erba H.P., Kantarjian H., Claxton D.F., et al. Phase II study of single agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy. ASH Annual Meeting Abstracts 2008, 112:558.
44. Anonymous FDA Advisory Committee recommends randomized trial to support proposed indication for clolar in adult AML September 1, 2009, Genzyme Press, Available at:, Accessed September 22, 2009. http://www.genzyme.com/corp/media/GENZ%20PR-090109.asp.
45. Faderl S., Garcia-Manero G., Ravandi F., et al. Oral (po) and intravenous (iv) clofarabine for patients (pts) with myelodysplastic syndrome (MDS). ASH Annual Meeting Abstracts 2008, 112:222.
46. Martin M.G., Uy G.L., Procknow E., et al. Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG. Bone Marrow Transplant 2009, 44:13.
47. Andersson BS, de Lima M, Popat U, et al. Allogeneic stem cell transplantation (allo-sct) for relapsed, refractory myeloid leukemia and MDS using clofarabine (clo) +/- fludarabine (flu) with iv busulfan (bu) as conditioning therapy. Presented at the 2009 BMT Tandem Meeting. Tampa, Florida, February, 2009. [Abstract #238].
48. Magenau J, Pawarode A, Buck T, et al. Conditioning with clofarabine and busulfan x 4 (clobu4) for non-remission hematologic malignancies including AML is well tolerated, facilitates secure engraftment, and exhibits significant anti-tumor activity. Presented at the 2009 BMT Tandem Meeting. Tampa, Florida, February, 2009. [Abstract #287].
49. van Besien K, Kline J, Godley L, et al. Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation (HCT) in patients with advanced hematologic malignancies: unexpected renal toxicity. Presented at the 2009 BMT Tandem Meeting. Tampa, Florida, February, 2009. [Abstract #290].
50. Raza A., Galili N., Smith S., et al. Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome. Blood 2009, 113:6533.
51. Ruscoe J.E., Rosario L.A., Wang T., et al. Pharmacologic or genetic manipulation of glutathione S-transferase P1-1 (GSTpi) influences cell proliferation pathways. J Pharmacol Exp Ther 2001, 298:339.
52. Raza A., Galili N., Callander N., et al. Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra(R), TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome. J Hematol Oncol 2009, 2:20.
53. Gate L., Lunk A., Tew K.D. Resistance to phorbol 12-myristate 13-acetate-induced cell growth arrest in an HL60 cell line chronically exposed to a glutathione S-transferase pi inhibitor. Biochem Pharmacol 2003, 65:1611.
54. O'Brien M.L., Vulevic B., Freer S., et al. Glutathione peptidomimetic drug modulator of multidrug resistance-associated protein. J Pharmacol Exp Ther 1999, 291:1348.
55. Pigneux A. Laromustine, a sulfonyl hydrolyzing alkylating prodrug for cancer therapy. IDrugs 2009, 12:39.
56. Giles F., Rizzieri D., Karp J., et al. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. J Clin Oncol 2007, 25:25.
57. Giles F., Verstovsek S., Faderl S., et al. A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia. Leuk Res 2006, 30:1591.
58. Giles F., Verstovsek S., Thomas D., et al. Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia. Clin Cancer Res 2005, 11:7817.
59. Feldman E.J. Farnesyltransferase inhibitors in myelodysplastic syndrome. Curr Hematol Rep 2005, 4:186.
60. Medeiros B.C., Landau H.J., Morrow M., et al. The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines. Leukemia 2007, 21:739.
61. Kurzrock R., Albitar M., Cortes J.E., et al. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol 2004, 22:1287.
62. Fenaux P., Raza A., Mufti G.J., et al. A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. Blood 2007, 109:4158.
63. Kurzrock R., Kantarjian H.M., Blascovich M.A., et al. Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome. Clin Cancer Res 2008, 14:509.
64. Ravoet C., Mineur P., Robin V., et al. Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study. Ann Hematol 2008, 87:881.